Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 17/20 | 0.58 |
| ▸ | MMP9 | P14780 | 17/20 | 0.49 |
| ▸ | MMP1 | P03956 | 11/20 | 0.49 |
| ▸ | MMP3 | P08254 | 2/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | PLA2G7 | Q13093 | 2/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7080614 | 0.82 | MMP2 (0.42) | MMP2MMP9MMP1MMP3MMP13 | |
| SCHEMBL7080694 | 0.78 | MMP2 (0.47) | MMP2MMP9MMP1MMP3MMP8 | |
| SCHEMBL6952582 | 0.77 | MMP2 (0.38) | MMP2MMP9MMP1MMP3MMP13 | |
| SCHEMBL7077657 | 0.74 | PLA2G7 (0.46) | MMP2MMP9MMP1MMP3MMP13 | |
| SCHEMBL6948525 | 0.74 | PLA2G7 (0.54) | MMP2MMP9MMP1MMP3MMP13 | |
| SCHEMBL7568536 | 0.73 | MMP2 (0.90) | MMP2MMP9MMP1MMP3 | |
| SCHEMBL7507327 | 0.73 | MMP2 (0.90) | MMP2MMP9MMP1MMP3 | |
| SCHEMBL7676418 | 0.73 | MMP2 (1.00) | MMP2MMP9MMP1 | |
| SCHEMBL6788586 | 0.72 | MMP2 (0.47) | MMP2MMP9MMP1MMP3MMP13 | |
| SCHEMBL7075454 | 0.72 | POLB (0.46) | MMP2MMP9MMP1MMP3MMP13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | OWEN DAVID ALAN (GB) | 2003-11-06 | — | — | US | claimed |
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | OWEN DAVID ALAN (GB) | 2003-11-06 | — | — | US | disclosed |
| US-6566384-B1 | For therapy of cancer, inflammation and inflammatory diseases, tissue degeneration, periodontal disease, ophthalmological disease, dermatological disorders, fever, cardiovascular effects, haemorrhage, coagulation and acute phase response | DARWIN DISCOVERY LTD. (GB) | 2003-05-20 | — | — | US | disclosed |
| US-6118001-A | ANTICANCER AGENT; ANTIARTHRITIC AGENT | DARWIN DISCOVERY, LTD. (GB) | 2000-09-12 | — | — | US | disclosed |
| EP-0968182-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | Darwin Discovery Limited (GB) | 2000-01-05 | — | — | EP | disclosed |
| WO-1998005635-A1 | HYDROXAMIC AND CARBOXYLIC ACID DERIVATIVES HAVING MMP AND TNF INHIBITORY ACTIVITY | DARWIN DISCOVERY LIMITED (GB) | 1998-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207889-A1 | Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity | MMP13, MMP2, MMP9 | MMP2 2/4885MMP9 3/4885MMP1 16/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.